Cisplatin is a first line chemotherapy for most types of cancer. However, its use is dose-limited due to severe nephrotoxicity. Here we report the rational engineering of a novel nanoplatinate inspired by the mechanisms underlying cisplatin bioactivation. We engineered a novel polymer, glucosamine-functionalized polyisobutylene-maleic acid, where platinum (Pt) can be complexed to the monomeric units using a monocarboxylato and an O → Pt coordinate bond. We show that at a unique platinum to polymer ratio, this complex self-assembles into a nanoparticle, which releases cisplatin in a pH-dependent manner. The nanoparticles are rapidly internalized into the endolysosomal compartment of cancer cells, and exhibit an IC50 (4.25 AE 0.16 μM) comparable to that of free cisplatin (3.87 AE 0.37 μM), and superior to carboplatin (14.75 AE 0.38 μM). The nanoparticles exhibited significantly improved antitumor efficacy in terms of tumor growth delay in breast and lung cancers and tumor regression in a K-ras LSL∕þ ∕Pten fl∕fl ovarian cancer model. Furthermore, the nanoparticle treatment resulted in reduced systemic and nephrotoxicity, validated by decreased biodistribution of platinum to the kidney as quantified using inductively coupled plasma spectroscopy. Given the universal need for a better platinate, we anticipate this coupling of nanotechnology and structureactivity relationship to rationally reengineer cisplatin could have a major impact globally in the clinical treatment of cancer.
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chemotherapy | nanomedicine | cancer I n the continuing search for effective treatments for cancer, an emerging paradigm is the use of nanotechnology to uncap the full potential of existing chemotherapy agents (1) . Integral physicochemical properties of nanovectors can be modulated to improve the antitumor efficacy of chemotherapeutic agents (2) . For example, the shape and size of nanostructures can play a deterministic role in the biological outcome (3) (4) (5) . Similarly, surface modifications to increase hydrophilicity can mask the nanovectors from the reticuloendothelial system, thereby increasing circulation time and altering the pharmacokinetics of the active agents (2) . Such nanovectors accumulate preferentially in the tumors due to the unique leaky tumor vasculature coupled with impaired intratumoral lymphatic drainage, which contributes to an enhanced permeation and retention (EPR) effect (6, 7) . Indeed, nanovectors were shown to deliver between 5-11× more doxorubicin to Kaposi sarcoma lesions than to normal skin (8) . Similarly, the tumor paclitaxel concentration-time area under the curve was found to be 33% higher when administered as an albumin-paclitaxel nanoparticle, and is currently approved for use in metastatic breast cancer (9) .
Cisplatin [cis-dichlorodiammineplatinum(II)] is one of the most commonly used chemotherapeutic agents besides doxorubicin and paclitaxel, and is a first line therapy for most malignancies, including testicular, ovarian, cervical, and lung cancer (10) . It was also shown recently to be effective in triple negative breast cancer (11) . Its clinical use, however, is dose-limited due to systemic toxicity, primarily to the kidney (12) . Consequently, developing an improved cisplatin has been a holy grail in cancer drug discovery. We rationalized that this challenge could be addressed by harnessing a nanotechnology-based strategy. It is now welldocumented that nanoparticles >5 nm will avoid renal clearance (13) , and thereby could potentially reduce cisplatin nephrotoxicity.
The development of a cisplatin nanoparticle has been a challenge resulting from its physicochemical properties, which make it difficult to entrap it in polymeric sustained-release nanoparticles (14, 15) . In a recent study, Dhar et al. generated a platinum (IV) complex (c;t;c-½PtðNH 3 Þ 2 ðO 2 CCH 2 CH 2 CH 2 CH 2 CH 3 Þ 2 Cl 2 ), which had sufficient hydrophobicity for encapsulation in PLGA-b-PEG nanoparticles, but the prodrug had to be intracellularly processed into cisplatin (16) . Alternative strategies based on the conjugation of platinum to polymers (for example, a polyamidoamine dendrimer-platinum complex), resulted in 200-550-fold reduction in cytotoxicity than free cisplatin as a result of strong bonds that are formed between the polymer and Pt (17) . Similarly, AP5280, a N-(2-hydroxypropyl) methacrylamide copolymer-bound platinum was found to exert minimal nephrotoxicity in clinical studies (18) , but was less potent than carboplatin as the platinum is held to an aminomalonic acid chelating agent coupled to the COOH-terminal glycine of a tetrapeptide spacer (19) . These studies also shed light on the impact of the complexation environment of the platinum on the efficacy. We used this structure-activity relationship underlying the activation of platinum to engineer a unique nanoplatinate that exhibited significantly improved antitumor efficacy in terms of tumor growth delay in lung and breast cancer and tumor regression in K-ras LSL∕þ ∕Pten fl∕fl ovarian cancer models, along with reduced systemic and nephrotoxicity.
Results
Cisplatin Bioactivation-Inspired Polymer Design for Nanoparticle Engineering. Cisplatin gets rapidly activated through intracellular aquation of the chloride leaving groups to form cis-½PtðNH 3 Þ 2 ClðOH 2 Þ þ and cis-½PtðNH 3 Þ 2 ðOH 2 Þ 2þ , following which Pt forms covalent bonds to the N7 position of purine bases to form prevalent GpG and ApG intrastrand and interstrand crosslinks (20) . In comparison, carboplatin and oxaliplatin have a cyclobutane-1, 1-dicarboxylato and an oxalate respectively as the leaving groups, which chelate the platinum more strongly conferring greater stability to the leaving group-Pt complex ( Fig. 1) (21) . As a result both carboplatin and oxaliplatin exhibit improved nephrotoxicity profile but also lesser efficacy than cisplatin (22, 23) . We rationalized that the design of a nanoparticle modeled on the leaving group would offer the greatest possibility of retaining the efficacy of cisplatin while the size of nanoparticle could bypass renal clearance and thereby reduce nephrotoxicity. As the first step, we identified a polymer, where each monomeric unit could serve as the leaving group of cisplatin. As shown in Fig. 1 , hydrolysis of poly-isobutylene-maleic anhydride, comprised of 40 units of maleic acid linked linearly through an isobutylene linker, resulted in the generation of poly-isobutylene-maleic acid (PIMA), where each monomer can be complexed to cis-½PtðNH 3 Þ 2 ðOH 2 Þ 2þ through dicarboxylato linkages. Complexing all 40 monomeric units of the polymer with Pt resulted in gelation. However, lower Pt to polymer ratio resulted in self-assembly into nanoparticles as revealed by dynamic laser light scatter (DLS), with the size being governed by the Pt:polymer unit ratio [ Fig. 2A] . At a Pt:polymer ratio of 15∶1, we obtained nanoparticles that were narrowly distributed in 80-140 nm size range. It is now well-established that nanoparticles in the optimal size range of 80-160 nm home preferentially into tumors resulting from the EPR effect (7), suggesting that the polymeric-cisplatin nanoparticle (PIMA-cisplatin) could potentially reduce systemic side effects and exhibit increased intratumoral delivery. We next tested the PIMA-cisplatin nanoparticle on a Lewis lung carcinoma cell line in vitro. As shown in Fig. 3A whereas PIMA-cisplatin nanoparticle induced cell kill, the efficacy was significantly lower than free cisplatin and similar to carboplatin, consistent with the stable dicarboxylato complexation between the platinum and the maleic acid monomers (22, 23) .
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Cisplatin Carboplatin Oxaliplatin Picoplatin Aroplatin Rational Optimization of the Polymer Based on Structure-Activity Relationship. As the next step, to improve efficacy of the nanoparticles, we rationalized that derivatizing one arm of each monomer unit of the polymer with biocompatible glucosamine to generate a PIMA-glucosamine conjugate (PIMA-GA) would convert the dicarboxylato bonds with Pt to a monocarboxylato bond and a coordinate bond, which should release Pt more easily (Fig. 1) . NMR characterization of the Pt environment revealed that complexation of PIMA-GA and cisplatin in an acidic pH generated an isomeric molecule, [PIMA-GA-cisplatin (O → Pt)], characterized by the monocarboxylato and a O → Pt coordination complex as indicated by a single Pt NMR peak at −1611.54 ppm. Complexing the cisplatin with PIMA-GA at an alkaline pH (pH 8.5) favored the formation of an isomeric PIMA-GA-cisplatin (N → Pt) complex, where the Pt is complexed through a monocarboxylato and a more stable N → Pt coordinate bond characterized by a unique peak at −2210 ppm. The possibility of generating these two pH-dependent states allowed us to further dissect the impact of Pt environment, specifically the leaving groups, on the biological efficacy. The complexation of cisplatin to PIMA-glucosamine (PIMA-GA) polymer at a ratio of 15∶1 resulted in selfassembly into nanoparticles in the desired narrow size bandwidth of 80-150 nm as confirmed by DLS (Fig. 2B ) and high-resolution transmission electron microscopy (TEM) (Fig. 2C) . Furthermore, we achieved a loading of 175 AE 5 μg∕mg of polymer (Fig. 2D) , which is significantly higher than can be achieved using traditional nanoparticle formulations (14, 15) .
Characterizing the Uptake and Efficacy of Nanoparticles In Vitro. To test the efficacy of the PIMA-GA-cisplatin nanoparticles in vitro, we performed cell viability assays using Lewis lung carcinoma (LLC) and 4T1 breast cancer cell lines. Cell viability was quantified using a 3- (Fig. 3) . A similar efficacy was observed when we replaced glucosamine with ethylene diamine, which creates a similar Pt complexation environment as glucosamine (Fig. 3A) . This was additionally supported by the observation that PIMA-GA-cisplatin (N → Pt) nanoparticles (IC50 ¼ 6.36 AE 0.19 μM) were significantly less active than cisplatin, suggesting that the platinum environment is critical in defining the rate of aquation. To further validate the role of complexation environment, we generated PIMA-GA (20) , where only 20 of the 40 monomers comprising a PIMA polymer were derivatized with glucosamine, thereby introducing a mixture of dicarboxylato bonds and monocarboxylato plus coordinate bonds that complex Pt to PIMA-GA. As shown in Fig. 3C , the concentration-efficacy curve shifts to the right with PIMA-GA(20)-cisplatin (IC50 ¼ 5.85 AE 0.13 μM) as compared with PIMA-GA-cisplatin (O → Pt) nanoparticles, where all the 40 monomers are derivatized with glucosamine. Empty PIMA-GA polymer had no effect on the cell viability. Labeling the cells for expression of phosphatidylserine on the cell surface revealed that the cisplatin nanoparticle treatment could induce apoptotic cell death, with LLCs being more susceptible than 4T1 cells (Fig. 3D and Fig. S1 ). Tagging the polymer with fluorescein (Fig. S2) enabled the temporal tracking of uptake of the nanoparticles into the cells, which were colabeled with a lysotracker-red dye to label the endolysosomal compartments. As shown in Fig. S2 , a rapid uptake of the nanoparticles and internalization into the endolysosomal compartment was observed in the LLC cells within 15 min of treatment with in contrast to 2 h in the case of 4T1 cells.
Release of Active Cisplatin from Nanoparticle Is pH-Dependent. As the nanoparticles localized to the lysosomal compartment, we tested the release of Pt from the nanoparticles at pH 5.5, mimicking the acidic pH of the endolysosomal compartment of the tumor (24) . We also selected pH 8.5 as a reference pH in the alkaline range. As shown in Fig. 4 , at pH 5.5 PIMA-GA-cisplatin (O → Pt) nanoparticles resulted in a sustained release of cisplatin monitored over a 70 h period. In contrast the release at pH 8.5 was significantly lower, indicating a pH-dependent release of Pt. PIMA- GA-cisplatin (N → Pt) released Pt at a slower rate even at pH 5.5, consistent with the fact that the N → Pt coordinate bond is stronger than the O → Pt linkage. As expected, we observed that PIMA-cisplatin nanoparticles exhibited significantly lower rates of Pt release as compared with both PIMA-GA-cisplatin (N → Pt) and PIMA-GA-cisplatin (O → Pt) as the Pt is held by more stable dicarboxylato bonds instead of a monocarboxylato and a coordinate bond.
Nanoparticle Induces Tumor Growth Delay and Regression with Reduced Nephrotoxicity. As PIMA-GA-cisplatin (O → Pt) nanoparticles exhibited the desired release rates for platinum and also exhibited in vitro efficacy comparable to cisplatin, we validated the therapeutic efficacy of these nanoparticles in vivo. Mice bearing established 4T1 breast cancer were randomized into five groups and treated thrice with (i) vehicle (PBS) control; (ii) Cisplatin (1.25 mg∕kg); (iii) Cisplatin (3 mg∕kg); (iv) PIMA-GACisplatin (O → Pt) nanoparticles (1.25 mg∕kg); and (v) PIMA-GA-Cisplatin (O → Pt) nanoparticles (3 mg∕kg). The mice injected with vehicle formed large tumors by day 16 and were euthanized. The animals in the other groups were also sacrificed at the same time point to evaluate the effect of the treatments on tumor pathology. As shown in Fig. 5 , whereas both free cisplatin and the cisplatin-nanoparticles exhibited similar tumor inhibition, the free drug resulted in a significant reduction in body weight indicating systemic toxicity. Furthermore, necropsy revealed that treatment with free cisplatin results in a significant reduction in the weights of kidney and spleen, indicating nephrotoxicity and hematotoxicity consistent with previous reports. In contrast, cisplatin nanoparticles had no effect on the weights of the kidneys or the spleen (Fig. 5 D and E) . To elucidate the mechanism underlying cytotoxicity, we TUNEL-stained tumor sections, which revealed a significant induction of apoptosis following treatment with both free cisplatin and PIMA-GA-cisplatin (O → Pt) nanoparticles (Fig. 5F ). Labeling the kidney sections for TUNEL validated significant apoptosis in the animals treated with free cisplatin as opposed to minimal nephrotoxicity in the nanoparticle-treated group (Fig. 5F ). Indeed, biodistribution studies using inductively coupled plasma-spectrometry revealed that the concentration of Pt in the kidney following administration of the cisplatin-nanoparticle is negligible as compared to that attained following administration of free drug (Fig. 5G) , which can explain the reduction in nephrotoxicity. Similarly, the concentration of platinum in the reticuloendothelial system (RES) was lower when administered as a nanoparticle as compared with free cisplatin or carboplatin, indicating that the nanoparticles can escape the RES. In a separate experiment, animals bearing Lewis lung carcinoma were similarly treated and exhibited similar superior outcome with the nanoparticles (Fig. S3) .
We next evaluated the PIMA-GA-cisplatin (O → Pt) nanoparticles in a K-ras LSL∕þ ∕Pten fl∕fl ovarian cancer model, in which cisplatin is a first line drug of choice. The discovery of frequent somatic PTEN mutations and loss of heterozygosity at the 10q23 PTEN locus in endometrioid ovarian cancer implicates a key role for PTEN in the etiology of this epithelial ovarian cancer subtype (25, 26) . Similarly, K-RAS oncogene is also mutated in endometrioid ovarian cancer, albeit at a lesser frequency (27) . In a recent study, the combination of these two mutations in the ovarian surface epithelium was found to induce invasive and widely metastatic endometrioid ovarian adenocarcinomas with complete penetrance, making it a good model for mimicking human tumor progression (28) . Vehicle-treated animals exhibited rapid tumor progression as quantified by luciferase expression. Treatment with the cisplatin-nanoparticles resulted in a dosedependent inhibition of tumor progression, with the lower dose equivalent to 1.25 mg∕kg exerting a similar inhibition as a 3 mg∕kg dose of free cisplatin (Fig. 6) . Treatment with the higher dose of cisplatin-nanoparticle (equivalent to 3 mg∕kg of cisplatin) resulted in greater tumor inhibition without any significant loss of body weight or nephrotoxicity (Fig. 6D ) compared with equi-dose of free cisplatin. Interestingly, we observed different levels of systemic toxicity in the different mouse strains, indicating distinct levels of susceptibility to the cytotoxic. This can potentially be explained by an enhanced distribution to the tumor with reduced clearance by the RES (Fig. 6E) .
Discussion
Despite the development of targeted therapeutics (29) , cytotoxic chemotherapeutics are still the first line therapy for all tumors. This necessitates novel strategies that can increase the therapeutic index of cytotoxics. In this study, we merged the mechanism of cisplatin bioactivation with the inherent advantages of nanotechnology to rationally engineer a unique polymeric nanoparticle that increases the therapeutic index of cisplatin. Furthermore, we used this platform to validate that the complexation environment of platinum plays a critical role in the efficacy of platinumbased cytotoxics. Cisplatin is one of the most commonly used cytotoxic agents in cancer chemotherapy, and exerts its activity by interfering with transcription and other DNA-mediated cellular functions (30) . In an elegant study, Davies et al. used a 1H-13N heteronuclear sequential quantum correlation NMR spectroscopy to demonstrate that aquation of cisplatin results in the rapid formation of cis-½PtðNH 3 Þ 2 ClðOH 2 Þ þ and cis-½PtðNH 3 Þ 2 ðOH 2 Þ 2þ (31) with a rate constant of 8 × 10 −5 s −1 . In contrast the rate constant for aquation of carboplatin was found to be 7.2 × 10 −7 s −1 . This difference in their rate of activation was matched by their rates of binding to DNA (21, 22) , which can explain the increased IC50 value of carboplatin compared with cisplatin (22) . This was further validated in our studies as the PIMA-cisplatin nanoparticles, where both the dicarboxylato and the monocarboxylato plus N → Pt linkages confer greater stability to the Pt-polymer complex as seen in the release kinetics experiments. In contrast, we demonstrate that the rational introduction of an O → Pt coordinate linkage facilitates rapid activation of platinum, which can explain the increased efficacy of the PIMA-GA-Cisplatin (O → Pt) nanoparticles. The EPR effect combined with the approximately 100 nm nanoparticle size that exceed the 5 nm cutoff for clearance by the kidney could potentially explain the preferential accumulation of the PIMA-GA-Cisplatin (O → Pt) nanoparticles in the tumor with decreased renal platinum concentration as observed in this study. Together with the rapid release of platinum, this can explain the increased antitumor efficacy of PIMA-GA-Cisplatin (O → Pt) nanoparticle compared with free cisplatin at lower concentrations and increased therapeutic index at the highest concentrations as seen in vivo.
In conclusion, we demonstrate that the rational engineering of a polymer inspired by the bioactivation of cisplatin enables the engineering of a unique nanoplatinate, which improves antitumor efficacy of cisplatin by capitalizing on the inherent properties of nanoscale. This opens up the possibility to increase the maximal tolerated dose of cisplatin, which is an effective chemotherapeutic agent but dose limited due to nephrotoxicity. The clinical familiarity of using an established and globally used chemotherapeutic, together with the low cost of the basic building blocks used in fabricating the nanoparticle, can facilitate the rapid translation of this technology, thereby validating the potential of nanotechnology to impact global health (32) .
Materials and Methods
Synthesis of Cisplatin Nanoparticles. Poly(isobutylene-alt-maleic anhydride) was dissolved in dry dimethylformamide (DMF) in round bottom flask to which double distilled water was added. Solvent was removed under vacuum and low molecular weight impurities were removed using dialysis (MWCO: 1000 KD, Spectrapor). The solution was then lyophilized to get poly(isobu tylene-alt-maleic acid) (PIMA). To generate PIMA-glucosamine polymer, poly(isobutylene-alt-maleic anhydride) was dissolved in DMF to which Diaza (1, 3) bicyclo [5.4 .0]undecane (DBU) and glucosamine was added. The resulting reaction mixture was allowed to stir at room temperature for 48 h and then quenched by adding double distilled water. The organic solvent was evaporated under vacuum. The resulting pale yellow solid was purified by dialysis. Nanoparticles were engineered by dissolving the polymers in double distilled water containing cisplatin for 48 h. The polymer-cisplatin conjugates were purified by dialysis. The dialyzed solutions were lyophilized, and resuspended to obtain the nanoparticles. The products were characterized at each step using 1 H, 13 In Vivo Murine Lewis Lung Carcinoma and 4T1 Breast Cancer Models. The LLC cells and 4T1 Breast cancer cells (3 × 10 5 ) were implanted subcutaneously in the flanks of 4-week-old C57/BL6 and BALB/c mice (weighing 20 g, Charles River Laboratories) respectively. The drug therapy was started on day 6 for LLC and day 9 for the 4T1 tumors. Free or nanoparticle cisplatin was administered through tail vein at doses equivalent to 1.25 and 3 mg∕kg of platinum in PBS (100 μL). The tumor volumes, calculated using formula L × B 2 , and body weights were monitored on a daily basis. The animals were sacrificed when the average tumor size of the control exceeded 2000 mm 3 in the control group. The tumors were harvested immediately following sacrifice and stored in 10% formalin for further analysis. All animal procedures were approved by the Harvard Institutional Use and Care of Animals Committee.
In Vivo Murine Ovarian Cancer Tumor Model. Ovarian adenocarcinomas were induced in genetically engineered K-ras LSL∕þ ∕Pten fl∕fl mice via intrabursal delivery of adenovirus carrying Cre recombinase, as described previously (28) . Tumor cells were engineered to express luciferase once activated by AdenoCre, to make tumor imaging feasible before and after drug treatment. Once mice developed medium to large tumors they were placed into one of four treatment groups (tumor imaging in vivo was performed with the IVIS Lumina II Imaging System). Quantification of bioluminescence was achieved by using the Living Image Software 3.1 (Caliper Life Sciences). Mice received 150 mg∕kg of D-luciferin firefly potassium salt via i.p. injection prior to imaging. Five min postluciferin injection, animals were anesthetized in a 2.5% isoflurane induction chamber. Once anesthesized, mice were placed into the imaging chamber where they were kept under anesthesia by a manifold supplying isoflurane and their body temperature was maintained by a 37°C temperature stage. Bioluminescent signal was collected 15 min after luciferin administration for an exposure time of 30 s. Images were taken a day prior to treatment (day 0, baseline) and 1 d following the final treatment. Toxicity Assessment of Drug Treatment. Body weights were recorded daily to assess toxicity. In addition, livers and spleens were removed at the end of treatment to record weights and perform extensive pathological examination to assess toxicity of vital organs. Cell apoptosis in vital organs was measured using TUNEL assay.
Statistical Analysis. Data were expressed as means AE S:D from at least n ¼ 3. Statistical analysis was conducted using the Prism software (GraphPad). The statistical differences were determined by ANOVA followed by Newman Keuls Post Hoc test or Student's t test. p < 0.05 was considered to indicate significant differences. 
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